-
Citius Oncology signs distribution deal with McKesson for LYMPHIR launch
-
Citius Oncology partners with EVERSANA for LYMPHIR drug launch
-
Citius Oncology partners with Integris Pharma for LYMPHIR access in Europe
-
Citius Oncology (CTOR) Files $200M Mixed Shelf
-
Citius Oncology deploys AI platform ahead of LYMPHIR launch
-
Citius Oncology signs distribution deal with Cencora for LYMPHIR
-
Citius Pharmaceuticals regains Nasdaq compliance
-
Citius Oncology (CTOR) Anticipates Commercial Launch of LYMPHIR in 2025
-
Citius Oncology (CTOR) stock soars on distribution deal
-
Citius (CTOR) enters distribution agreement with Cardinal Health (CAH)
-
Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
-
Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) Highlight LYMPHIR Commercial Launch Planned for H1 of 2025
-
Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) Report Prelim Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab and LYMPHIR

